The Non Infectious Macular Edema Treatment Market To Stabilize Post Stumbling Am

Posted by Ashish on January 21st, 2021

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular edema, which is a severe case of swelling in the retina possibly leading to blindness. Looking at the significant increase in the number of macular edema cases, many new drugs have been introduced in the global market and several are still in the pipeline.

Anti-VEGF and corticosteroid therapies are considered to be the standard therapies for prevention of vision loss in patients in various indications of macular edema. The other drug types that are part of the macular edema treatment market are immunosuppressant and biologics, and many new treatment types are expected to be introduced as the market continues to grow.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22984

Company Profiles

• Allergan, Plc.
• Amgen, Inc.
• Pfizer, Inc.
• Novartis AG
• F. Hoffman – La Roche Ltd.
• AbbVie Inc.
• Bayer AG
• Valeant Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Clearside Biomedical, Inc.